Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Next Previous
X
Search
Trial Profile

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Age-related macular degeneration; Eye disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors QLT

    • Most Recent Events

    • 05 Dec 2014 Primary endpoint has not been met (low luminance low contrast best-corrected visual acuity [LLLC BCVA] measured at multiple time points), according to a QLT media release.
    • 05 Dec 2014 Results published in a QLT media release.
    • 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top